The modern pharmaceutical company announced that it expects offer your vaccine against COVID-19 at a price of between 32 ($ 121,000) and $ 37 (140,000) per dose, a “pandemic price”, which will depend on the volume requested by each country and hopes to guarantee its universal access.
“We are working with governments around the world and with others to make sure the vaccine is accessible regardless of the ability to pay “, assured in a call with investors the CEO of Moderna, Stephane Bancel.
The price will be lower for those countries that request large volumes of doses, said the company, clarifying that a “small” order, for which the price range announced this Wednesday would apply, would be in the order of several million doses.
That price is above the $ 19.50 (72,000) Pfizer advanced. for the vaccine that it develops together with the German BioNTech and that is, as in the case of Moderna, at the beginning of phase 3, the final stretch of clinical tests to certify its reliability and safety.
Moderna’s announcement came at the presentation of the results for the second quarter of the year, in which the Massachusetts-based company multiplied its revenue by five to $ 66.4 million.
That cut the net loss by 13% to $ 116.7 million or $ 0.31 per share.
At the end of July, Moderna had already received $ 400 million in deposits to supply the mRNA-1273 vaccine, the distribution of which is already negotiating with several interested countries.
The US government has disbursed $ 483 million in April and a further $ 472 million thereafter. for the development of your vaccine.
Moderna collaborates with the National Institutes of Health (NIH) in the development and clinical trials of the mRNA.1273 vaccine, which uses messenger RNA technology and has shown promising results in the first tests with humans.